PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25928802-3 2015 The aim of this study is to explain, from a mechanistic point of view, the clinical evidence showing a significant role of glutathione-S-transferase (GST)-M1 genotype on AZA toxicity in inflammatory bowel disease patients. Azathioprine 170-173 glutathione S-transferase kappa 1 Homo sapiens 123-148 30987408-12 2019 In conclusion, GSTs variants are associated with azathioprine efficacy and pharmacokinetics. Azathioprine 49-61 glutathione S-transferase kappa 1 Homo sapiens 15-19 26432087-0 2015 The impact of glutathione S-transferase genotype and phenotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases. Azathioprine 96-108 glutathione S-transferase kappa 1 Homo sapiens 14-39 26432087-4 2015 Glutathione S-transferase (GST) mutation is another pharmacogenetic polymorphism which is probably involved in AZA metabolism and tolerance. Azathioprine 111-114 glutathione S-transferase kappa 1 Homo sapiens 0-25 26432087-4 2015 Glutathione S-transferase (GST) mutation is another pharmacogenetic polymorphism which is probably involved in AZA metabolism and tolerance. Azathioprine 111-114 glutathione S-transferase kappa 1 Homo sapiens 27-30 26432087-5 2015 The aim of this study was to investigate the association among GST polymorphism, enzyme activity and AZA-related ADRs in Chinese Han patients with IBD. Azathioprine 101-104 glutathione S-transferase kappa 1 Homo sapiens 63-66 26432087-8 2015 The patients with higher GST activity constituted a pharmacogenetic high risk group for leucopenia during AZA treatment. Azathioprine 106-109 glutathione S-transferase kappa 1 Homo sapiens 25-28 25928802-3 2015 The aim of this study is to explain, from a mechanistic point of view, the clinical evidence showing a significant role of glutathione-S-transferase (GST)-M1 genotype on AZA toxicity in inflammatory bowel disease patients. Azathioprine 170-173 glutathione S-transferase kappa 1 Homo sapiens 150-153 25928802-7 2015 In this study, an in vitro model to study thiopurines" metabolism has been set up and helped us to demonstrate, for the first time, a clear role of GST-M1 in modulating AZA cytotoxicity, with a close dependency on superoxide anion production. Azathioprine 169-172 glutathione S-transferase kappa 1 Homo sapiens 148-151 25928802-8 2015 These results provide the molecular basis to shed light on the clinical evidence suggesting a role of GST-M1 genotype in influencing the toxic effects of AZA treatment. Azathioprine 154-157 glutathione S-transferase kappa 1 Homo sapiens 102-105 24707136-5 2014 In addition to increase the activation of azathioprine to mercaptopurine, GSTs may contribute to azathioprine effects even by modulating GSH consumption, oxidative stress and apoptosis. Azathioprine 97-109 glutathione S-transferase kappa 1 Homo sapiens 74-78 24707136-6 2014 Therefore, genetic polymorphisms in genes for GSTs may be useful to predict response to azathioprine even if more in vitro and clinical validation studies are needed. Azathioprine 88-100 glutathione S-transferase kappa 1 Homo sapiens 46-50 17493759-1 2007 Glutathione transferases (GSTs) catalyze the bioactivation of the thiopurine prodrugs azathioprine, cis-6-(2-acetylvinylthio)purine (cAVTP) and trans-6-(2-acetylvinylthio)guanine (tAVTG), thereby releasing the antimetabolites 6-mercaptopurine and 6-thioguanine. Azathioprine 86-98 glutathione S-transferase kappa 1 Homo sapiens 26-30 17206640-2 2007 Azathioprine is known to induce glutathione depletion and consumption of glutathione is greater in cells with high glutathione-S-transferase (GST) activity compared with those with low activity; moreover, some reports indicate that GST might play a direct role in the reaction of glutathione with azathioprine. Azathioprine 0-12 glutathione S-transferase kappa 1 Homo sapiens 115-140 17206640-2 2007 Azathioprine is known to induce glutathione depletion and consumption of glutathione is greater in cells with high glutathione-S-transferase (GST) activity compared with those with low activity; moreover, some reports indicate that GST might play a direct role in the reaction of glutathione with azathioprine. Azathioprine 0-12 glutathione S-transferase kappa 1 Homo sapiens 142-145 17206640-2 2007 Azathioprine is known to induce glutathione depletion and consumption of glutathione is greater in cells with high glutathione-S-transferase (GST) activity compared with those with low activity; moreover, some reports indicate that GST might play a direct role in the reaction of glutathione with azathioprine. Azathioprine 0-12 glutathione S-transferase kappa 1 Homo sapiens 232-235 17206640-2 2007 Azathioprine is known to induce glutathione depletion and consumption of glutathione is greater in cells with high glutathione-S-transferase (GST) activity compared with those with low activity; moreover, some reports indicate that GST might play a direct role in the reaction of glutathione with azathioprine. Azathioprine 297-309 glutathione S-transferase kappa 1 Homo sapiens 115-140 17206640-2 2007 Azathioprine is known to induce glutathione depletion and consumption of glutathione is greater in cells with high glutathione-S-transferase (GST) activity compared with those with low activity; moreover, some reports indicate that GST might play a direct role in the reaction of glutathione with azathioprine. Azathioprine 297-309 glutathione S-transferase kappa 1 Homo sapiens 142-145 17206640-2 2007 Azathioprine is known to induce glutathione depletion and consumption of glutathione is greater in cells with high glutathione-S-transferase (GST) activity compared with those with low activity; moreover, some reports indicate that GST might play a direct role in the reaction of glutathione with azathioprine. Azathioprine 297-309 glutathione S-transferase kappa 1 Homo sapiens 232-235 17206640-3 2007 The association between polymorphisms of GST-M1, GST-P1, GST-T1, and TPMT genes and the adverse effects of azathioprine was therefore investigated. Azathioprine 107-119 glutathione S-transferase kappa 1 Homo sapiens 41-44 17206640-6 2007 RESULTS: Fifteen patients developed adverse effects (21.4%); there was a significant underrepresentation of the GST-M1 null genotype among patients developing adverse drug reactions to azathioprine (odds ratio [OR] = 0.18, 95% confidence interval [CI] = 0.037-0.72, P = 0.0072) compared with patients who did not develop adverse effects. Azathioprine 185-197 glutathione S-transferase kappa 1 Homo sapiens 112-115 17206640-8 2007 Moreover, among the 55 patients who did not develop adverse effects, there was a significant underrepresentation of the GST-M1 null genotype among patients who displayed lymphopenia as compared with those that did not display this effect of azathioprine (OR = 0.15, 95% CI = 0.013-1.08, P = 0.032). Azathioprine 241-253 glutathione S-transferase kappa 1 Homo sapiens 120-123 17206640-9 2007 CONCLUSION: Patients with IBD with a wildtype GST-M1 genotype present increased probability of developing adverse effects and increased incidence of lymphopenia during azathioprine treatment. Azathioprine 168-180 glutathione S-transferase kappa 1 Homo sapiens 46-49